Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .
用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。
Tanta University Hospital, Tanta, El-Gharbia Governorate, Egypt
Faculty of medicine, Tanta University, Tanta, El-Gharbia, Egypt
Faculty of Medicine, Menoufia University, Shibīn Al Kawm, Menoufia, Egypt
Obafemi Awolowo University, Ile-Ife, Osun, Nigeria
Panax Clinical Research, Miami Lakes, Florida, United States
Orlando Clinical Research Center, Orlando, Florida, United States
Panax Clinical Research, Miami Lakes, Florida, United States
Orlando Clinical Research Center, Orlando, Florida, United States
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic
Hospital de Infectología "Daniel Méndez Hernández" del Centro Médico Nacional La Raza, Ciudad de Mexico, Azcapotzalco, Mexico
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.